Deepak Nitrite has accepted the resignation of Puneet Sharma from his position as SBU Head - Life Sciences, effective close of business on August 21, 2026.

The company disclosed the change under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sharma served in the role overseeing the Life Sciences division, which includes agrochemical and pharma intermediates, personal care, and emerging platforms.

Resignation Details

Sharma tendered his resignation on May 23, 2026, citing a decision to pursue an opportunity outside the organization for the next chapter of his career. He completed a three-month contractual notice period before his relieving date.

In his resignation letter addressed to Maulik Mehta, Sharma highlighted his tenure at Deepak Nitrite as a defining phase of his professional life. He noted the trust and autonomy extended by management during his time shaping the division.

Transition Plan

Sharma committed to ensuring a seamless transition process. This includes covering ongoing business development engagements with global innovators and maintaining progress on technology platforms. He stated he would work closely with management to onboard his successor.

The disclosure was signed by Arvind Bajpai, Company Secretary, on August 21, 2026.

Deepak Nitrite Limited delivered its highest-ever quarterly performance in Q1FY27, reporting a consolidated net profit of ₹345.01 crore, a 207% year-on-year surge from ₹112.25 crore in Q1FY26. The chemical manufacturer's total revenue climbed 35% to ₹2,591.61 crore, supported by strong domestic realisations and improved product spreads. This result underscores the company's ability to navigate global supply chain volatility through strategic backward integration and disciplined cost management, offering significant upside for shareholders amidst robust operational leverage.

The Board of Directors approved the unaudited financial results on August 4, 2026. Deloitte Haskins & Sells LLP, the statutory auditors, issued a limited review report confirming no material misstatements under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Subsequently, pursuant to Regulation 30 of the same regulations, the company uploaded the audio recording of the Q1 & FY 2027 Earnings Conference Call held on August 6, 2026, to its website.

Key Financial Highlights

The following table summarises the consolidated financial performance for the quarter:

Segmental Performance

The Phenolics segment remained the primary growth driver, delivering record quarterly revenue of ₹1,775.05 crore and an EBIT of ₹417.76 crore, up significantly YoY from ₹117.90 crore. This was aided by favourable benzene input positioning and high operating rates. The Advanced Intermediates segment also showed robust health, with revenue rising 33% to ₹803.85 crore and EBIT doubling to ₹66.98 crore from ₹35.47 crore in the prior year period. The domestic-to-export revenue mix stood at 85:15, reflecting strong local demand visibility.

Strategic Integration and Capacity Expansion

During the earnings call, management highlighted the successful completion and stabilization of the ammonia-to-amines integration chain. Deputy Managing Director Maulik Mehta stated that the company is no longer just a nitration entity buying nitric acid but has evolved into a nitrogen company that nitrates. This shift materially strengthens supply security and structural cost competitiveness.

Key developments include:

• Phenol Capacity: The phenol plant has reached a capacity of close to 4 lakh tonnes. Management confirmed achieving a quarterly run rate of 1 lakh tonnes during parts of Q1, despite raw material volatility. Further debottlenecking investments of ₹70–₹100 crore are planned to sustain this output.
• New Commissions: MIBK and MIBC projects are scheduled for commissioning in August 2026, alongside acetophenone. These assets will strengthen downstream integration and broaden the product basket.
• Polycarbonate Project: India’s first integrated polycarbonate project is progressing as per the roadmap. Management targets commissioning in H2 FY29 (calendar year 2028-2029), with Bisphenol A (BPA) following shortly after.

Capital Allocation and Funding

Sanjay Upadhyay, Director (Finance) & Group CFO, disclosed that the ongoing propylene and polycarbonate project involves a total capex of ₹11,500 crore, funded via a 60:40 debt-equity ratio. As of Q1FY27, approximately ₹1,200 crore has been spent. The company plans to spend another ₹1,000–₹1,500 crore this year, bringing total spend to around ₹3,200 crore. Peak debt is expected to reach ₹8,000–₹8,500 crore, including working capital, with a comfortable debt-to-equity ratio below 1x.

What the Numbers Show

The disproportionate expansion in net profit (207%) compared to revenue growth (35%) highlights significant operational leverage and margin improvement. The EBITDA margin more than doubled to 21.5% from 11.3% YoY, driven by higher sales realisations in select products and cost optimisation measures. Notably, renewable energy investments began yielding tangible benefits, contributing approximately ₹4.5 crore in cost savings during the quarter. While finance costs increased to ₹22.91 crore from ₹8.13 crore YoY, this was fully offset by the surge in operating profits. The company's strategy of securing long-term feedstock agreements continues to insulate margins from external price volatilities.